/w=3840,quality=90,fit=scale-down)
/w=3840,quality=90,fit=scale-down)
Raphael Thys
Myotis daubentonii. (Credit: Generate Biomedicines)Proteins are an essential part of life. Not only do they function as the “building blocks” for living organisms, but they also perform nearly every cellular task, from waste management to tissue repair. It tracks, then, that pharmaceuticals often contain or “target” proteins in an attempt to change or eliminate symptoms or disease within the body. There’s just one little problem: The only proteins we can use to create drugs are the ones we know.
But what if we could add new proteins to the resource pile? Two biotech labs have begun using artificial intelligence (AI) to generate novel proteins with the goal of incorporating them into medicine. Chroma, a program by Boston-based Generate Biomedicines, and RoseTTAFold Diffusion, a program out of the University of Washington’s Baker Lab, are often compared with trendy AI art generators thanks to their ability to create new concepts seemingly out of thin air. In fact, Chroma has even been referred to as “the DALL-E 2 of biology.”
AI protein generators, a type of denoising diffusion probabilistic model (DDPM), are trained to pull samples from complex datasets. They then use those samples—plus added noise—to construct a product that matches a given prompt. Although art generators are the best-known DDPMs, AI isn’t only good for producing images on demand; they’ve also been found to be an ideal method of generating diverse protein models. In a preprint on bioRxiv, Baker Labs scientists describe how RoseTTAFold can devise protein structures with virtually any desired size, shape, or function, as well as with any required constraints.
A protein generated by RoseTTAFold (left) with its lab recreation (right). (Credit: Baker Lab)
Chroma works similarly. Generate Biomedicine’s program pulls from what it calls the Protein Data Bank, which houses 3D protein and protein complex structures as well as amino acid sequences. Using the patterns from this data, Chroma can create new proteins within size, symmetry, and function constraints. Seemingly capable of heavier lifts than its competitor, Chroma uses a single commodity GPU to generate large proteins and protein complexes in just a few minutes.
Once RoseTTAFold or Chroma generates a protein, scientists can bring that protein to life in the lab. Baker Lab says it has already synthesized hundreds of RoseTTAFold’s creations, many of which have the potential to be “useful as medications, vaccines, or even new nanomaterials.” Some of Baker Lab’s proteins even attach to essential hormones better than existing protein-based drugs, offering hope that AI-generated proteins might someday enable the creation of more effective pharmaceuticals.
Now Read: